April 2018

New Product - Qtern

Qtern (saxagliptin/dapagliflozin) combines saxagliptin and dapagliflozin with distinct and complementary mechanisms of action to improve glycaemic control. Saxagliptin, through the selective inhibition of DPP-4, enhances glucose mediated insulin secretion (incretin effect). Dapagliflozin, a selective inhibitor of SGLT2, inhibits renal glucose reabsorption independently of insulin. Qtern is indicated as an adjunct to diet and exercise, in combination with metformin, to improve glycaemic control in adults with T2DM when treatment with both saxagliptin and dapagliflozin is appropriate. Qtern is contraindicated with hypersensitivity (including anaphylaxis or angioedema) following exposure to any DPP-4 inhibitor. Qtern should not be used in patients with CrCl persistently < 60 mL/min or eGFR persistently < 60 mL/min/1.73 m², as the efficacy of dapagliflozin is dependent on renal function. Qtern 5 mg/10 mg fixed dose combination tablets are available in packs of 28.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au